Internalization of ACE2 and hypofibrinolysis can lead to reduced degradation of bradykinin (KER2352), raising bradykinin levels and activities (KE 1867, Bradykinin system, hyperactivated), which could explain many of the symptoms associated with COVID-19, including vasodilation, hypotension, vascular permeability and hyperinflammation (KER2357). The gene discussed is KNG1; the disease is COVID-19.